8VTE

Co-structure of the Fab of the anti-TIGIT Vibostolimab antibody with its antigen

8VTE の概要

• エントリーDOI: 10.2210/pdb8vte/pdb
• 分子名称: Tiragolumab antibody light chain variable domains, Tiragolumab antibody heavy chain variable domains, T-cell immunoreceptor with Ig and ITIM domains, ... (4 entities in total)
• 機能のキーワード: antibody tigit immunotherapy, immune system
• 由来する生物種: Mus musculus (house mouse); 詳細
• タンパク質・核酸の鎖数: 6
• 化学式量合計: 124714.55

構造登録者

Fischmann, T.,Bahmanjah, S. (登録日: 2024-01-26, 公開日: 2025-05-28, 最終更新日: 2025-09-03)

主引用文献

Fischmann, T.O.,Malashock, D.,Ahn, E.,Wang, H.,Pradhan, K.,Grein, J.,Chakravorty, S.,Bahmanjah, S.,Ban, D.,Chien, E.,Hsieh, M.,Mayhood, T.,Yuan, J.,Wong, J.C.,Beaumont, M.,Baker, J.,McCoy, M.A.,Cai, M.,Wilson, D.,Blumenschein, W.,Williams, S.M.G.,Fayadat-Dilman, L.,Seghezzi, W.,Keenan, T.,Han, J.H.
Pharmacological and structural characterization of vibostolimab, a novel anti-TIGIT blocking antibody for cancer immunotherapy.
J Immunother Cancer, 13:-, 2025

PubMed Abstract: Vibostolimab is a humanized anti-T cell immunoreceptor with immunoglobulin (Ig) and ITIM domains (TIGIT) antibody was recently investigated in late-stage clinical trials. Vibostolimab was developed based on its specific binding property to the human and cynomolgus monkey TIGIT protein and its functional blocking activity of the TIGIT:CD155 interaction.

PubMed: 40829901
DOI: 10.1136/jitc-2024-008972

実験手法

X-RAY DIFFRACTION (2.29 Å)